Biomarker panel flags aggressiveness of ovarian cancer cases; New research predicts fast growth for biomarker business;

> A team at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute has built up a 10-gene biomarker panel for ovarian cancer that can be used to determine the aggressiveness of an individual's disease. Release

> A new report from Allied Market Research concludes that the biomarker business for diagnostics will hit $30.6 billion by 2020. The business is growing at an annual rate of 16%. Release

> Biothera says it's been building up its knowledge of a biomarker that could be used to help identify patients most likely to respond to their late-stage immunotherapy Imprime PGG, which is being studied for colorectal cancer. Release

Suggested Articles

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.

Cybernet Manufacturing, maker of medical-grade computer monitors, has unveiled a new, large touchscreen designed to protect against infections.

A startup has raised $12 million to fund its real-time system for monitoring patients undergoing dialysis at home and calling in complications.